Grufity logoGrufity logo

LNTH

56.01USD-5.26(-8.58%)Market Closed

Lantheus Holdings Inc

Market Summary

USD56.01-5.26Market Closed
-8.58%

LNTH Alerts

LNTH Stock Price

RSI Chart

Valuation

Market Cap

5.2B

Price/Earnings

160.13

Price/Sales

7.81

Price/Cashflow

51.31

MarketCap/EBT

87.76

Price/Sales

Profitability

EBT Margin

8.90%

Return on Equity

5.71%

Return on Assets

3.19%

Fundamentals

Revenue

Revenue (TTM)

664.2M

Revenue Y/Y

121.37%

Revenue Q/Q

7.11%

Earnings

Earnings (TTM)

32.4M

Earnings Y/Y

261.53%

Earnings Q/Q

0.22%

Price Action

52 Week Range

23.5187.47
(Low)(High)

Last 7 days

-8.0%

Last 30 days

-7.6%

Last 90 days

-29.5%

Trailing 12 Months

111.4%

Financial Health

Current Ratio

1.85

Debt/Equity

0.27

Debt/Cashflow

0.65

Investor Care

Shares Dilution (1Y)

1.68%

Diluted EPS (TTM)

0.42

Peers (Alternatives to Lantheus Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.3B
31.3B
8.50% -14.15%
27.1
5.87
11.35% 14.95%
174.5B
45.0B
7.48% -17.73%
20.4
3.83
6.43% 8.90%
115.4B
30.8B
-6.92% -24.79%
22.17
3.71
-3.11% -8.14%
30.3B
3.3B
13.59% -28.00%
45.68
9.17
6.53% -11.52%
16.7B
2.9B
11.16% -44.82%
26.46
5.74
8.50% 2.96%
MID-CAP
6.4B
806.4M
30.84% -10.95%
-331.15
7.96
20.10% -221.96%
5.2B
664.2M
-7.57% 111.36%
160.13
7.81
76.53% 218.01%
3.7B
2.3B
3.07% -36.74%
3.27
1.42
24.87% 6.11%
SMALL-CAP
1.4B
527.2M
16.14% -59.87%
29.31
2.69
12.53% -20.65%
1.4B
233.4M
1.11% -71.27%
-4.82
6.12
8.78% -318.40%
1.4B
333.0M
-0.03% 63.27%
32.26
4.08
4.76% -40.54%
765.9M
259.0M
3.86% -58.24%
-43.31
2.97
3.62% -967.02%
44.3M
7.9M
-6.19% -78.95%
-1.23
5.93
23.02% -7.81%
17.5M
37.6M
-62.35% -99.14%
-0.13
0.46
1.85% -22.51%

Financials for Lantheus Holdings

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue22.6%664542425390376
Gross Profit33.3%368276188168162
  S&GA Expenses13.2%8475686256
  R&D Expenses5.7%4947454647
Earnings Before Taxes287.8%59-31.48-75.04-36.87-24.50
Net Income186.8%32-37.33-71.28-34.48-27.45
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets8.6%1,014933864848858
  Current Assets24.5%404325236202186
    Cash Equivalents62.7%171105999192
  Inventory-0.8%3434353432
  Net PPE-117----
  Goodwill0%6161616161
Liabilities7.0%446417399348350
  Current Liabilities23.3%219178907774
  Long Term Debt-2.3%156159175167169
    LT Debt, Current9.2%1413121010
    LT Debt, Non Current-163----
Shareholder's Equity10.0%567516464499508
  Retained Earnings24.2%-135.21-178.26-221.22-181.01-167.59
  Additional Paid-In Capital1.2%700692685681676
Accumulated Depreciation-89----
Shares Outstanding0.2%6969686868
Float-1,850----
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations86.0%101,09054,36253,91640,59644,831
  Share Based Compensation15.5%21,06418,24015,93415,39515,520
Cashflow From Investing-15.3%-12,697.00-11,010.003,6834,4423,126
Cashflow From Financing-19.3%-8,016.00-6,720.00-39,332.00-41,605.00-47,149.00

Risks

What is the probability of a big loss on LNTH?

86.2%


Probability that Lantheus Holdings stock will be more than 20% underwater in next one year

57.7%


Probability that Lantheus Holdings stock will be more than 30% underwater in next one year.

32.7%


Probability that Lantheus Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LNTH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Lantheus Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on LNTH

47.5%


7-Year Cumulative Returns

21.9%


5-Year Cumulative Returns

39.9%


3-Year Cumulative Returns

What are the long-term rolling returns for LNTH?

FIve years rolling returns for Lantheus Holdings.

Which funds bought or sold LNTH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
B. Riley Wealth Advisors, Inc.
NEW
-
268,000
268,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,286,000
1,286,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.1
307,000
6,055,000
0.01%
2022-11-17
M&T Bank Corp
REDUCED
-8.92
20,000
419,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
REDUCED
-17.89
-271,000
1,889,000
0.01%
2022-11-16
Front Row Advisors LLC
NEW
-
2,000
2,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
306,000
306,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
ADDED
7.58
18,000
143,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
2,826.52
184,078,000
190,179,000
0.09%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
85.79
8,083,360
16,341,200
0.03%

1–10 of 44

Latest Funds Activity

Are funds buying LNTH calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own LNTH

Lantheus Holdings News

Digital Journal

Networking Products Market Size, Growth, Share : Global Sales Revenue, Emerging Technologies, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2029.19 hours ago

LNTH Fair Value

Recent SEC filings of Lantheus Holdings

View All Filings
Date Filed Form Type Document
Nov 21, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 15, 2022
4
Insider Trading
Nov 14, 2022
8-K
Current Report
Nov 10, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report
Oct 20, 2022
4
Insider Trading
Oct 20, 2022
4
Insider Trading

Latest Insider Trading transactions for LNTH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
Blanchfield Paul
SOLD
-133,249
54.79
-2,432
Chief Operating Officer
2022-11-15
Marshall Robert J. Jr.
SOLD
-295,000
59
-5,000
CFO and Treasurer
2022-11-15
Sabens Andrea
SOLD
-22,774
59
-386
Chief Accounting Officer
2022-11-11
Niedzwiecki Daniel
SOLD
-179,190
59.73
-3,000
See Remarks
2022-11-08
Heino Mary Anne
SOLD
-752,365
57.2141
-13,150
President & CEO
2022-10-19
Montagut Etienne
SOLD
-238,696
71.81
-3,324
Chief Business Officer
2022-10-18
Marshall Robert J. Jr.
SOLD
-354,443
73.414
-4,828
CFO and Treasurer
2022-10-18
Montagut Etienne
SOLD
-186,178
73.414
-2,536
Chief Business Officer
2022-10-17
Sabens Andrea
SOLD
-27,213
70.5
-386
Chief Accounting Officer
2022-09-15
Sabens Andrea
SOLD
-33,130.4
85.83
-386
Chief Accounting Officer

1–10 of 50

Mary A. Heino
610
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

LNTH Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenues$ 239,292$ 102,073$ 671,895$ 295,646
Cost of goods sold91,85959,404257,363165,859
Gross profit147,43342,669414,532129,787
Operating expenses    
Sales and marketing25,41417,19573,26048,999
General and administrative23,75928,55093,94587,865
Research and development12,51711,25239,45533,673
Total operating expenses61,69056,997206,660170,537
Gain on sale of assets00015,263
Operating income (loss)85,743(14,328)207,872(25,487)
Interest expense1,6261,5694,6046,224
Gain on extinguishment of debt000(889)
Other income1,1013,9403063,209
Income (loss) before income taxes83,016(19,837)202,962(34,031)
Income tax expense (benefit)21,784(6,422)55,710(2,967)
Net income (loss)$ 61,232$ (13,415)$ 147,252$ (31,064)
Net income (loss) per common share:    
Basic (in dollars per share)$ 0.89$ (0.20)$ 2.15$ (0.46)
Diluted (in dollars per share)$ 0.86$ (0.20)$ 2.08$ (0.46)
Weighted-average common shares outstanding:    
Basic (in shares)68,75667,62368,48267,409
Diluted (in shares)71,07567,62370,66967,409

LNTH Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 257,259$ 98,508
Accounts receivable, net197,27689,336
Inventory34,79335,129
Other current assets12,57012,818
Total current assets501,898235,791
Property, plant and equipment, net120,826116,772
Intangibles, net323,591348,510
Goodwill61,18961,189
Deferred tax assets, net46,80662,764
Other long-term assets41,62838,758
Total assets1,095,938863,784
Current liabilities  
Current portion of long-term debt and other borrowings15,37211,642
Accounts payable30,13520,787
Accrued expenses and other liabilities190,47758,068
Total current liabilities235,98490,497
Asset retirement obligations23,35820,833
Long-term debt, net and other borrowings152,057163,121
Other long-term liabilities46,489124,894
Total liabilities457,888399,345
Commitments and contingencies (See Note $19)
Stockholders’ equity  
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)00
Common stock ($0.01 par value, 250,000 shares authorized; 68,809 and 67,739 shares issued and outstanding, respectively)688677
Additional paid-in capital708,341685,472
Accumulated deficit(73,973)(221,225)
Accumulated other comprehensive income (loss)2,994(485)
Total stockholders’ equity638,050464,439
Total liabilities and stockholders’ equity$ 1,095,938$ 863,784